This article is more than 5 years old. Information may no longer be current.
Allergan pharma sales up 25% for third quarter
Click Here to Manage Email Alerts
IRVINE, Calif. — Allergan’s pharmaceutical sales in the third quarter of 2005 increased 25% from the third quarter of 2004, with net sales of $606.1 million, the company said in a press release.
Eye care pharmaceuticals accounted for the largest share of sales, at $358.1 million, compared with $285.4 million in the third quarter 2004.
Glaucoma drugs Alphagan P (brimonidine tartrate), Alphagan (brimonidine 0.2%) and Combigan (0.2% brimonidine tartrate, 0.5% timolol maleate) led sales, totaling $75.1 million during the quarter. Lumigan (bimatoprost ophthalmic solution 0.03%) sales were $72.8 million, up from $60.3 million in the third quarter of 2004. At $54 million, dry eye treatment Restasis (cyclosporine) more than doubled its sales from $24.1 million in the third quarter of 2004.
Botox (botulinum toxin type A) sales also increased during the quarter, to $214.8 million from $174.6 million in the year-ago period.
Highlights for the quarter, according to the press release, included Food and Drug Administration premarket approval for Alphagan P 0.1%, positive opinions from European regulators for Combigan, and the beginning of a multi-year agreement with Sirna Therapeutics to develop an RNA-interference compound for the treatment of age-related macular degeneration.